China runs the world's most active regulated stem cell research programme — and a large grey-market of unproven clinics. The legitimate pathway, the red flags, and how to tell them apart.
Stem cell therapy in China splits into two worlds. The legitimate pathway is investigator-initiated and registered clinical trials conducted at top Class A academic centres under the National Medical Products Administration (NMPA) and the Health Commission's dual-track regulatory framework — primarily mesenchymal stem cell (MSC) therapy for osteoarthritis, graft-versus-host disease and selected autoimmune conditions. The grey-market pathway — clinics promising stem cell cures for autism, ALS, MS, or anti-ageing — is unregulated, unproven and to be avoided.
The Short Answer
Stem cell therapy in China splits into two worlds. The legitimate pathway is investigator-initiated and registered clinical trials conducted at top Class A academic centres under the National Medical Products Administration (NMPA) and the Health Commission's dual-track regulatory framework — primarily mesenchymal stem cell (MSC) therapy for osteoarthritis, graft-versus-host disease and selected autoimmune conditions. The grey-market pathway — clinics promising stem cell cures for autism, ALS, MS, or anti-ageing — is unregulated, unproven and to be avoided.
What's Approved and Regulated
Under the dual-track regulatory framework introduced in 2017 and expanded since 2022, two distinct routes exist:
- Drug track (NMPA) — stem cell products developed as pharmaceuticals; require formal clinical trials and product registration. Several MSC products are in phase II/III trials.
- Clinical research track (National Health Commission) — investigator-initiated trials at qualified Class A teaching hospitals. ~140 hospitals are registered to conduct stem cell clinical research.
Conditions Where Evidence Is Strongest
- Knee osteoarthritis — autologous bone-marrow-derived MSCs; growing phase II/III data for moderate OA.
- Steroid-refractory graft-versus-host disease — established clinical use post-allogeneic HSCT.
- Critical limb ischemia, perianal Crohn's fistula — emerging indications with registered trials.
Conditions to Avoid Marketed "Stem Cell Cures" For
- Autism / ASD.
- Cerebral palsy.
- Multiple sclerosis (outside registered HSCT protocols).
- Anti-ageing / "stem cell facial".
- Spinal cord injury (outside registered trials).
No high-quality randomised data supports stem cell therapy for any of these indications. Clinics that promote them are charging for unproven treatment.
How to Tell a Legitimate Programme From a Grey-Market Clinic
- Where is it delivered? Legitimate stem cell therapy in China is delivered at a NHC-registered Class A teaching hospital — not a stand-alone "stem cell clinic".
- Is there a trial registration? Ask for the ChiCTR (Chinese Clinical Trial Registry) or ClinicalTrials.gov registration number.
- Is informed consent documented? Legitimate research protocols always provide an English-language informed consent form, ethics committee approval, and protocol summary.
- Is the cell source clearly defined? Autologous bone-marrow MSC, allogeneic umbilical-cord MSC, and induced pluripotent (iPSC) products have different evidence and regulatory profiles.
- Are outcomes tracked? Legitimate programmes follow patients at fixed intervals using validated outcome measures (WOMAC, KOOS, ODI, etc.).
Typical Cost (Regulated Pathway)
USD 6,500–12,000 all-in for autologous MSC therapy at a Class A teaching hospital, including workup, cell processing, injection, and a 12-month follow-up programme. Clinics outside this regulatory frame may quote anywhere from USD 3,000 to USD 60,000 with no published outcome data — buyer beware.
For our editorial position and the patient pathway for the regulated route, see stem cell therapy in China and the research overview. For one international patient's regulated MSC pathway, see F. (52, UAE) — knee MSC therapy at HKU-Shenzhen.
Sources: National Medical Products Administration stem cell regulatory framework (2017–2025); National Health Commission stem cell clinical research filing list; ChiCTR registered stem cell trials; ISSCR Guidelines for Stem Cell Research and Clinical Translation.